A new compound drug could be effective in treating hepatitis C by attacking RNA that allows the virus to gain traction in a patient's body. The drug, miravirsen, targets the body's microRNA-122, preventing viral replication, according to findings published in the New England Journal of Medicine. The treatment could potentially also treat other serious diseases, including cancer. "This is really a revolution in science and it's now beginning to be translated into advances that control disease," said Phillip Sharp, an MIT molecular biologist who won a 1993 Nobel Prize for work on RNA.
Drug treats hepatitis C by targeting body's RNA
SmartBrief Job Listings for Education
|San Francisco Unified is Accepting Applications for 2015-16!||
San Francisco Unified School District
|San Francisco, CA|
|Director of Professional Services||
Engaging Schools, Inc.
|Principal at Emerson Academy of Dayton||
National Heritage Academies
|Program Officer, Teacher Development||
Knowles Science Teaching Foundation
|Senior Researcher (8194)||
American Institute for Researcher